Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL1331129

CCCCCCCCn1cc[n+](C)c1.O=S(=O)([O-])C(F)(F)F

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.68
HSP90AA1 P07900 2/20 0.68
KMT2A Q03164 2/20 0.68
SMN1; SMN2 Q16637 2/20 0.68
APAF1 O14727 1/20 0.68
NPC1 O15118 1/20 0.68
PLA2G1B P04054 1/20 0.68
MAPT P10636 1/20 0.68
MAPK1 P28482 1/20 0.68
HTT P42858 1/20 0.68
RAB9A P51151 1/20 0.68
NPSR1 Q6W5P4 1/20 0.68
ATG4B Q9Y4P1 1/20 0.68
KCNH2 Q12809 7/20 0.46
FDPS P14324 10/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL318566 1.00 MEN1 (0.68) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL318175 1.00 MEN1 (0.68) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL318764 1.00 MEN1 (0.68) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL318767 1.00 MEN1 (0.68) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL514445 1.00 MEN1 (0.68) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL3615950 0.99 MEN1 (0.65) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL1293510 0.96 MEN1 (0.62) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL294105 0.94 MEN1 (0.58) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL29390371 0.94 MEN1 (0.58) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Sulfuric Acid SCHEMBL31650730 0.90 MEN1 (0.78) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12172147-B2 Catalyst composition for selective hydrogenation with improved characteristics Sud Chemie, Inc. (US) 2024-12-24 US claimed
US-12172148-B2 Catalyst composition for selective hydrogenation with improved characteristics Sud Chemie, Inc. (US) 2024-12-24 US claimed
CN-116217298-B Modified tea saponin foliar fertilizer auxiliary agent 上饶师范学院 2024-07-16 CN claimed
CN-116217298-A Modified tea saponin foliar fertilizer auxiliary agent 上饶师范学院 2023-06-06 CN claimed
US-11634370-B2 Selective hydrogenation methods CLARIANT INTERNATIONAL LTD (CH) 2023-04-25 US claimed
US-11623902-B2 Selective hydrogenation methods and catalysts CLARIANT INTERNATIONAL LTD (CH) 2023-04-11 US claimed
CN-115768737-A Selective hydrogenation process 科莱恩国际有限公司 2023-03-07 CN claimed
CN-115715280-A Selective hydrogenation process and catalyst 科莱恩国际有限公司 2023-02-24 CN claimed
US-11567385-B2 Electrochromic device THE BOEING COMPANY (US) 2023-01-31 US claimed
CN-115305602-A White oil removing method for ultra-high molecular weight polyethylene fiber gel silk 九州星际科技有限公司 2022-11-08 CN claimed
US-20130341561-A1 ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY CUSTOMARRAY, INC. (US) 2013-12-26 US claimed
WO-2013057244-A1 CATALYST COMPOSITION FOR SELECTIVE HYDROGENATION WITH IMPROVED CHARACTERISTICS CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2013-04-25 WO claimed
US-20130102819-A1 CATALYST COMPOSITION FOR SELECTIVE HYDROGENATION WITH IMPROVED CHARACTERISTICS CLARIANT CORPORATION 2013-04-25 US claimed
EP-2583751-A1 Catalyst composition for selective hydrogenation with improved characteristics Clariant Produkte (Deutschland) GmbH (DE) 2013-04-24 EP claimed
WO-2012113778-A1 PROCESS FOR THE HYDROHALOGENATION OF AN ALKYNE AND FOR THE MANUFACTURE OF VINYL CHLORIDE BY HYDROCHLORINATION OF ACETYLENE SOLVAY SA (BE) 2012-08-30 WO claimed
WO-2012084644-A1 CATALYTIC SYSTEM AND ITS USE FOR THE MANUFACTURE OF VINYL CHLORIDE BY HYDROCHLORINATION OF ACETYLENE SOLVAY SA (BE) 2012-06-28 WO claimed
US-7718579-B2 Electrochemical deblocking using a hydrazine derivative COMBIMATRIX CORPORATION (US) 2010-05-18 US claimed
US-20070034513-A1 Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array COMBIMATRIX CORPORATION 2007-02-15 US claimed
WO-2007006418-A1 IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2007-01-18 WO claimed
US-20060054511-A1 Electrochemical deblocking using a hydrazine derivative CUSTOMARRAY, INC. 2006-03-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12172147-B2 Catalyst composition for selective hydrogenation with improved characteristics BET1, EP300, H1-2 MEN1 2422/4885HSP90AA1 3150/4885KMT2A 274/4885
US-12172148-B2 Catalyst composition for selective hydrogenation with improved characteristics BET1, EP300, H1-2 MEN1 2422/4885HSP90AA1 3150/4885KMT2A 274/4885
US-11634370-B2 Selective hydrogenation methods KAT8, KAT7, TDO2 MEN1 3450/4885HSP90AA1 958/4885KMT2A 1386/4885
US-11623902-B2 Selective hydrogenation methods and catalysts KAT8, ITGAV, ASNS MEN1 3316/4885HSP90AA1 1370/4885KMT2A 877/4885
US-20130102819-A1 CATALYST COMPOSITION FOR SELECTIVE HYDROGENATION WITH IMPROVED CHARACTERISTICS BET1, EP300, H1-2 MEN1 2439/4885HSP90AA1 3040/4885KMT2A 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.